Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 125

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 125
---
 liabilities based on our involvement in any future operations. The materialization of any of these risks could materially harm our performance and prospects. We may be subject to legal proceedings and litigation, including product or service liability claims, which are costly to defend and could materially affect our business and results of operations. We may be party to lawsuits and legal proceedings in the normal course of business. These matters are often expensive and disruptive to normal business operations. We may face allegations, lawsuits, and regulatory inquiries, audits, and investigations regarding data privacy, security, labor and employment, consumer protection, practice of medicine, and intellectual property infringement, including claims related to privacy, patents, publicity, trademarks, copyrights, open -sourcesoftware, and other rights. A portion of the technologies we use incorporates open -sourcesoftware, and we may face claims claiming ownership of open source software or patents related to that software, rights to our intellectual property or breach of open source license terms, including a demand to release material portions of our source code or otherwise seeking to enforce the terms of the applicable open source license. We may also face allegations or litigation related to our acquisitions, securities issuances or business practices, including public disclosures about our business. We are also at risk of lawsuits on the basis of product or professional liability, in particular arising out of Rewell. Our business depends on our ability to provide reliable and accurate test results, including tests that incorporate rapidly evolving information about the role of genes and gene variants in disease and clinically relevant outcomes associated with these variants. Hundreds of genes can be implicated in some disorders. Overlapping networks of genes and symptoms can be implicated in multiple conditions. As a result, and particularly with respect to pathology tests, substantial judgment is required in order to interpret the results of each test we perform and produce a report summarizing these results. Errors, such as failures to detect genomic variants with high accuracy, or mistakes, such as failures to completely and correctly identify the significance of gene variants or to detect disease via our diagnostics tests, could subject us to product liability or professional liability claims. Any such claim against us could result in substantial damages and be costly and time -consumingto defend, especially in jurisdictions such as Argentina that have robust consumer protection legislation in place. Although we annually review our terms and conditions and practices to ensure alignment with current legislation and maintain liability insurance, including for errors and 41 omissions, we may still face, and our insurance may not fully protect us from the financial impact of defending against, these types of claims or any judgments, fines,